Advertisement

Digestive Diseases and Sciences

, Volume 52, Issue 10, pp 2472–2477 | Cite as

Liver Transplantation Using Hepatitis B Core Antibody−Positive Grafts: Review and University of Tokyo Experience

  • Nobuyuki Takemura
  • Yasuhiko Sugawara
  • Sumihito Tamura
  • Masatoshi Makuuchi
Review Paper

Abstract

Hepatitis B surface antigen−negative and hepatitis B core antibody−positive grafts were considered unsuitable for transplantation. The number of potential recipients for liver transplantation now exceeds that of potential donor organs, which has led us to reevaluate the feasibility of these grafts. Several strategies involving prophylactic administration of hepatitis B immunoglobulin and/or lamivudine to transplant recipients have been proposed. At the University of Tokyo, we have continued to use hepatitis B immunoglobulin monoprophylaxis with zero recurrence.In this article we report our experience with the use of hepatitis B surface antigen−negative/hepatitis B core antibody−positive grafts with hepatitis B immunoglobulin monotherapy. We conducted a review of the literature regarding the feasibility of these grafts to reconfirm optimal prophylactic strategies for preventing de novo hepatitis B virus infection in transplant recipients.

Keywords

Hepatitis B virus De novo hepatitis Living donor liver transplantation Hepatitis B core antibody Hepatitis B immunoglobulin 

Abbreviations

HBV:

Hepatitis B virus

LDLT:

Living donor liver transplantation

HBcAb:

Hepatitis B core antibody

HBsAb:

Hepatitis B surface antibody

HBsAg:

Hepatitis B surface antigen

HBIG:

Hepatitis B immunoglobulin

Notes

Acknowledgments

This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Grants-in-aid for Research on HIV/AIDS, a multicenter pilot clinical study to compare the safety and efficacy of a steroid-free immunosuppression protocol with monoclonal anti-IL2R antibody in HCV-positive living donor liver transplantation and Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan.

References

  1. 1.
    Douglas DD, Rakela J, Mamish D, et al. (1992) Transmission of hepatitis B virus (HBV) infection from orthotopic donor livers. Hepatology 16:49CrossRefGoogle Scholar
  2. 2.
    Chazouilleres O, Mamish D, Kim M, et al. (1994) Occult hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142–146PubMedCrossRefGoogle Scholar
  3. 3.
    Wachs ME, Amend WJ, Ascher NL, et al. (1995) The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 59:230–234PubMedCrossRefGoogle Scholar
  4. 4.
    Radomski JS, Moritz MJ, Armenti VT, et al. (1996) Hepatitis B transmission from a liver donor who tested negative for hepatitis B surface antigen and positive for hepatitis B core antibody. Liver Transpl Surg 2:130–131PubMedCrossRefGoogle Scholar
  5. 5.
    Dickson RC, Everhart JE, Lake JR, et al. (1997) Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 113:1668–1674PubMedCrossRefGoogle Scholar
  6. 6.
    Dodson SF, Issa S, Araya V, et al. (1997) Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 64:1582–1584PubMedCrossRefGoogle Scholar
  7. 7.
    Uemoto S, Sugiyama K, Marusawa H, et al. (1998) Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65:494–499PubMedCrossRefGoogle Scholar
  8. 8.
    Prieto M, Gomez MD, Berenguer M, et al. (2001) De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 7:51–58PubMedCrossRefGoogle Scholar
  9. 9.
    Manzarbeitia C, Reich DJ, Ortiz JA, et al. (2002) Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 8:556–561PubMedCrossRefGoogle Scholar
  10. 10.
    Chen YS, Wang CC, de Villa VH, et al. (2002) Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 16:405–409PubMedCrossRefGoogle Scholar
  11. 11.
    Dodson SF, Bonham CA, Geller DA, et al. (1999) Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68:1058–1061PubMedCrossRefGoogle Scholar
  12. 12.
    Yu AS, Vierling JM, Colquhoun SD, et al. (2001) Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 7:513–517PubMedCrossRefGoogle Scholar
  13. 13.
    Loss GE, Mason AL, Blazek J, et al. (2001) Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 15:55–58PubMedCrossRefGoogle Scholar
  14. 14.
    Holt D, Thomas R, Van Thiel D, et al. (2002) Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 137:572–575PubMedCrossRefGoogle Scholar
  15. 15.
    Roque-Afonso AM, Feray C, Samuel D, et al. (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95–99PubMedCrossRefGoogle Scholar
  16. 16.
    Fabrega E, Garcia-Suarez C, Guerra A, et al. (2003) Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 9:916–920PubMedCrossRefGoogle Scholar
  17. 17.
    Nery JR, Nery-Avila C, Reddy KR, et al. (2003) Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 75:1179–1186PubMedCrossRefGoogle Scholar
  18. 18.
    de Villa VH, Chen YS, Chen CL (2003) Hepatitis B core antibody-positive grafts: recipient’s risk. Transplantation 75:49–53CrossRefGoogle Scholar
  19. 19.
    Lee KW, Lee DS, Lee HH, et al. (2004) Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 36:2311–2312PubMedCrossRefGoogle Scholar
  20. 20.
    Jain A, Orloff M, Abt P, et al. (2005) Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 37:3187–3189PubMedCrossRefGoogle Scholar
  21. 21.
    Donataccio D, Roggen F, De Reyck C, et al. (2006) Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 19:38–43PubMedCrossRefGoogle Scholar
  22. 22.
    Suehiro T, Shimada M, Kishikawa K, et al. (2005) Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 25:1169–1174PubMedCrossRefGoogle Scholar
  23. 23.
    Yen RD, Bonatti H, Mendez J, et al. (2006) Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 6:1077–1083PubMedCrossRefGoogle Scholar
  24. 24.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW (2006) Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 20:369–373PubMedCrossRefGoogle Scholar
  25. 25.
    Nery JR, Gedaly R, Vianna R, et al. (2001) Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation? Transplant Proc 33:1521–1522PubMedCrossRefGoogle Scholar
  26. 26.
    Burton JR Jr, Shaw-Stiffel TA (2003) Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 9:837–842PubMedCrossRefGoogle Scholar
  27. 27.
    van Thiel DH, De Maria N, Colantoni A, et al. (1999) Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 68:519–522PubMedCrossRefGoogle Scholar
  28. 28.
    Marusawa H, Uemoto S, Hijikata M, et al. (2000) Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31:488–495PubMedCrossRefGoogle Scholar
  29. 29.
    Chalasani N, Smallwood G, Halcomb J, et al. (1998) Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 4:128–132PubMedCrossRefGoogle Scholar
  30. 30.
    Dominguez M, Barcena R, Garcia M, et al. (2000) Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 6:440–442PubMedCrossRefGoogle Scholar
  31. 31.
    Carey W, Pimentel R, Westveer MK, et al. (1990) Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol 85:1590–1592PubMedGoogle Scholar
  32. 32.
    van Thiel DH, El-Ashmawy L, Love K, et al. (1992) Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 37:1245–1249PubMedCrossRefGoogle Scholar
  33. 33.
    Loinaz C, de Juanes JR, Gonzalez EM, et al. (1997) Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterol 44:235–238Google Scholar
  34. 34.
    Chalasani N, Smallwood G, Halcomb J, et al. (1998) Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 4:128–132PubMedCrossRefGoogle Scholar
  35. 35.
    Horlander JC, Boyle N, Manam R, et al. (1999) Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 318:304–307PubMedCrossRefGoogle Scholar
  36. 36.
    Dominguez M, Barcena R, Garcia M, et al. (2000) Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 6:440–442PubMedCrossRefGoogle Scholar
  37. 37.
    Villeneuve E, Vincelette J, Villeneuve JP (2000) Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 14:59–62Google Scholar
  38. 38.
    Arslan M, Wiesner RH, Sievers C, et al. (2001) Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 7:314–320PubMedCrossRefGoogle Scholar
  39. 39.
    Centers for Disease Control (CDC) (1988) Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep 37:377–382Google Scholar
  40. 40.
    Barcena R, Moraleda G, Moreno J, et al. (2006) Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 12:2070–2074PubMedGoogle Scholar
  41. 41.
    Moraleda G, Barcena R, Del Campo S, et al. (2006) De novo HBV infection caused by an anti-HBc positive donor in a vaccinated liver transplant recipient in spite of anti-HBs response. Am J Transplant 6:438–440PubMedCrossRefGoogle Scholar
  42. 42.
    Carman WF, Zanetti AR, Karayiannis P, et al. (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329PubMedCrossRefGoogle Scholar
  43. 43.
    Angus P, Vaughan R, Xiong S, et al. (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292–297PubMedCrossRefGoogle Scholar
  44. 44.
    Toniutto P, Fumo E, Caldato M, et al. (2004) Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 77:472–473PubMedCrossRefGoogle Scholar
  45. 45.
    Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, et al. (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419–1427PubMedGoogle Scholar
  46. 46.
    Lo CM, Liu CL, Lau GK, et al. (2005) Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 11:807–813PubMedCrossRefGoogle Scholar
  47. 47.
    Chang TT, Gish RG, de Man R, et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010PubMedCrossRefGoogle Scholar
  48. 48.
    Lai CL, Leung N, Teo EK, et al. (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528–536PubMedCrossRefGoogle Scholar
  49. 49.
    van Bommel F, Zollner B, Sarrazin C, et al. (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBVDNA level during adefovir therapy. Hepatology 44:318–325PubMedCrossRefGoogle Scholar
  50. 50.
    Tenney DJ, Levine SM, Rose RE, et al. (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48:3498–3507PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Nobuyuki Takemura
    • 1
  • Yasuhiko Sugawara
    • 1
  • Sumihito Tamura
    • 1
  • Masatoshi Makuuchi
    • 1
  1. 1.Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of MedicineUniversity of TokyoTokyoJapan

Personalised recommendations